NovaGo Therapeutics

Executive Summary

NovaGo Therapeutics is a Swiss biotech company founded in 2015 and headquartered in Basel, focusing on antibody therapeutics that promote nerve regeneration following spinal cord injury (SCI). The company's lead program targets the Nogo-A receptor, an endogenous inhibitor of central nervous system repair. By blocking this receptor, NovaGo aims to enhance axonal growth and functional recovery after SCI. The company is currently Phase 1 stage and is privately held. No financial details or valuation are publicly available, but the science is supported by strong preclinical evidence and the Nogo-A pathway is a well-validated target in neuroregeneration. There are currently no approved therapies that significantly improve neurological outcomes after SCI, representing a high unmet medical need.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 clinical trial data readout70% success
• Q4 2026Presentation at a major medical conference (e.g., ASGCT, SFN)50% success
• H2 2026Partnership or licensing deal for further development30% success